<DOC>
	<DOCNO>NCT01594229</DOCNO>
	<brief_summary>This Phase 1 , open-label , multicenter study evaluate safety , pharmacokinetic profile , preliminary efficacy ABT-199 combination Bendamustine/Rituximab approximately 60 subject relapsed refractory non-Hodgkin 's lymphoma . This study evaluate safety pharmacokinetic profile ABT-199 approximately 60 subject administer combination Bendamustine/Rituximab follow dose escalation scheme , objective define dose limit toxicity maximum tolerate dose .</brief_summary>
	<brief_title>A Study Evaluating Safety Pharmacokinetics ABT-199 Combination With Bendamustine/Rituximab ( BR ) Subjects With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Subject must histologically document diagnosis nonHodgkin 's lymphoma define Bcell neoplasm World Health Organization classification scheme except noted exclusion criterion . Subject ( nondiffuse large Bcell lymphoma ) must relapse refractory nonHodgkin 's lymphoma , require treatment opinion investigator . Subject diffuse large Bcell lymphoma must relapse diffuse large Bcell lymphoma must progress salvage therapy ( without standard chemotherapy ) diffuse large Bcell lymphoma . The subject must receive first line therapy RituximabCyclophosphamide , Hydroxydaunomycin , Vincristine ( Oncovin ) , Prednisone ( RCHOP ) [ similar standard rituximabcontaining frontline chemoimmunotherapy regimen include , limited Etoposide , Prednisone , Vincristine ( Oncovin ) , Cyclophosphamide , Doxorubicin ( Hydrochloride ) + Rituximab ( EPOCH + R ) ; Rituximab , Cyclophosphamide , Etoposide , Procarbazine , Prednisone ( RCEPP ) ; Rituximab , Cyclophosphamide , Mitoxantrone ( Novantrone ) , Vincristine ( Oncovin ) , Prednisone ( RCNOP ) ; DoseadjustedEtoposide , Prednisone , Vincristine ( Oncovin ) , Cyclophosphamide , Doxorubicin ( Hydrocloride ) ( DAEPOCH ) ; Rituximab , Cyclophosphamide , Etoposide , Vincristine ( Oncovin ) , Prednisone ( RCEOP ) ] . Subject must adequate coagulation , renal , hepatic function , per laboratory reference range Screening . Subject diagnose PostTransplant Lymphoproliferative Disease , Burkitt 's lymphoma , Burkittlike lymphoma , lymphoblastic lymphoma/leukemia , chronic lymphocytic leukemia , small lymphocytic lymphoma mantle cell lymphoma ( MCL ) . Subject refractory diffuse large Bcell lymphoma , define meeting follow criterion : Subject progress within 3 month completion plan course firstline therapy RituximabCyclophosphamide , Hydroxydaunomycin , Vincristine ( Oncovin ) , Prednisone ( RCHOP ) equivalent regimen ; Subject response ( i.e. , stable disease ) firstline therapy RCyclophosphamide , Hydroxydaunomycin , Vincristine ( Oncovin ) , Prednisone ( RCHOP ) equivalent regimen ; Subject progress within 2 month completion last planned course salvage therapy chemotherapy ( without rituximab , may include autologous stem cell transplant ) . Subject test positive human immunodeficiency virus ( HIV ) . Subject cardiovascular disability status New York Heart Association Class great equal 2 . Class 2 define cardiac disease patient comfortable rest ordinary physical activity , result fatigue , palpitation , dyspnea anginal pain . Subject significant history renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , hepatic disease opinion Investigator would adversely affect his/her participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ABT-199</keyword>
	<keyword>Cancer</keyword>
	<keyword>Preliminary Efficacy</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Safety</keyword>
</DOC>